KDR and neoplasm: Although itraconazole is known to inhibit VEGFR-2 phosphorylation, thereby blocking VEGF/VEGFR-2 binding, the observed increase in VEGFR-2 levels during the current study may attributed to a compensatory up-regulation adaptive response mediated by tumor cells.